Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Amy Schefler
Cytopathology and Prognostic Accuracy of 15-GEP/PRAME : The Collaborative Ocular Oncology Group Study 2
Cytopathology and Prognostic Accuracy of 15-GEP/PRAME: The Collaborative Ocular Oncology Group Study 2 Key Points Question Is confirmatory cytopathology associated with the prognostic accuracy of a 15-gene expression profile (15-GEP)/Preferentially Expressed Antigen in Melanoma (PRAME) classifier in predicting metastatic uveal melanoma risk?
Early Genetic Evolution of Driver Mutations in Uveal Melanoma
J.J.D, C.L.D., E.W., M.A.M., T.S.F., A.H.S., D.A.R., I.K., K.D.P., H.N., T.A.A., P.M., B.K.W., E.S., S.C.N.O., J.W., D.S.G., J.M., S.D.W., T.T., Z.M.C. and J.W.H. have acted as consultants for Castle Biosciences. K.R.C. is employed by Castle Biosciences. J.W.H. has received royalties for intellectual property related to prognostic testing in uveal melanoma that was licensed to Castle Biosciences. The remaining authors declare no competing interests.
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab
Amy C. Schefler, Dwain Fuller, Rajiv Anand, Timothy Fuller, Chelsey Moore, Jose Munoz, and Ryan S. Kim are RRR Study Group members. Address correspondence to Amy C. Schefler, MD, 4460 Bissonnet Street, Suite 200, Houston, TX 77401; acsmd@retinaconsultantstexas.com .
Prostaglandin-Induced Macular Hole: A Brief Report
Address correspondence to Amy C. Schefler, MD, Retina Consultants of Texas, 4460 Bissonnet Street, Suite 200, Houston, TX, 77401; email: acsmd@retinaconsultantstexas.com . From the Department of Ophthalmology, Baylor College of Medicine, Houston, Texas (AFA, JTA); Retina Consultants of Texas, Houston, Texas (TPW, ACS); and Blanton Eye Institute, Weill Cornell Medicine, Houston Methodist Hospital, Houston, Texas (ACS).
Overview of late complications of radiation therapy in uveal melanoma
Published by AME Publishing Company Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China. Email: editor@thecco.net
Overview of late complications of radiation therapy in uveal melanoma
The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader). Alternatively, you can also download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link below. If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.
Overview of late complications of radiation therapy in uveal melanoma
Published by AME Publishing Company Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China. Email: editor@thecco.net
Overview of late complications of radiation therapy in uveal melanoma
Introduction Traditionally, the local treatment of uveal melanoma was primarily managed with enucleation. The treatment paradigm shifted to radiotherapy after a series of Collaborative Ocular Melanoma Study (COMS) trials established eye plaque brachytherapy as a standard treatment option, demonstrating no significant difference in outcome metrics while preserving the globe and visual function.
Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status
Clinical Science Abstract BACKGROUND AND OBJECTIVE: The purpose of this study was to evaluate the association between clinical and ultrasound features of uveal melanoma and preferentially expressed antigen in melanoma (PRAME), given its role as a biomarker for metastatic mortality. MATERIALS AND METHODS: Ultrasonographic characteristics and PRAME expression status of patients with uveal melanoma (2016 to 2021) were retrospectively analyzed using univariate and multivariate regression.
Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling
Practice points The multicenter Clinical Application of DecisionDx-UM Gene Expression Assay Results study provides prospective validation of the clinical utility of the 15-gene expression profile test in directing metastatic surveillance imaging, follow-up and referral patterns. Medical oncology referral was more common for high-risk class 2 patients compared with class 1 patients (p < 0.001).
Early study results positive for AU-011 in patients with choroidal melanoma
VANCOUVER, British Columbia — A phase 1b/2 clinical trial of AU-011, a light-activated, vision-sparing, tumor cell selective therapy for patients with choroidal melanoma, showed the treatment was safe and resulted in no vision loss for up to 12 months, according to a speaker here. “AU-011 appears to be safe in early trials and is well tolerated. There is inflammation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Amy
Contact Amy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack